IMPROVING THE CLASSIFICATION OF PSORIASIS SEVERITY
The current clinical definitions of psoriasis severity are narrowly defined and overlook the unique challenges faced by each patient, which may include localized lesions in specific areas and/or comorbidities. A more specific clinical severity classification is needed and would guide clinical decision-making to be more practical, meaningful, and better aligned with the true severity of a patient’s disease; strengthen psoriasis treatment guidelines and guide future clinical trials of drugs targeting various severities of psoriasis.
In Phase I of the project, the Delphi method was used to come to consensus, among IPC’s network of key opinion leaders, on a definition for each category of disease severity. As the result of the reclassification Delphi, IPC recommends that patients be considered a candidate for topical-only therapy or a candidate for systemic therapy.
Patients that meet one or more of the following criteria are candidates for systemic therapy:
In Phase II of the project, the working group is focusing on implementing studies that quantify the statement in real-world practice. In addition, significant work is being done to educate clinicians and patients on the new classification. Future work in Phase II will focus on educating regulatory bodies and developing additional activities to educate clinicians and patients.
PSORIASIS INVOLVING SPECIAL AREAS IS ASSOCIATED WITH WORSE QUALITY OF LIFE, DEPRESSION, AND LIMITATIONS IN THE ABILITY TO PARTICIPATE IN SOCIAL ROLES AND ACTIVITIES
|Blauvelt A, Gondo G, Bell S, et al. Journal of Psoriasis and Psoriatic Arthritis. 2023;8(3):100-106. doi:10.1177/24755303231160683.
Psoriasis severity has traditionally been categorized as mild, moderate, and severe. Commonly, cut-offs for severe disease require a body surface area (BSA) involvement of ≥10% or a Psoriasis Area Severity Index (PASI) > 10. However, clinical experience challenges these traditional measures and requirements, as patients with less extensive psoriasis may have disease that severely impacts quality of life.
The objective of the present study was to further explore the extent of patient burden when psoriasis affects special locations.
A total of 69,190 individuals living in the U.S were invited to participate in a patient advocacy survey by telephone and or web interviews over the course of 3 years (2019-2021). The survey instrument consisted of validated patient-reported outcome measures, measuring disease-specific quality of life (Dermatology Life Quality Index, DLQI), depression (Patient Health Questionnaire (PHQ)-2 and (PHQ)-9), and the ability to participate in social roles and activities (PROMIS Ability to Participate in Social Roles and Activities (SF-4a). Chi-square tests were performed to explore association between psoriasis involvement on special locations and patient outcomes and multivariate logistic regression models were then constructed, to assess impact of having psoriasis on special locations patient outcomes, controlling for potential confounding factors.
A total of 4129 individuals completed the survey. 3594 (84.4%) of patients surveyed reported psoriasis involving special areas of the bodysuch as the scalp, face, hands, feet, or genitalia. Involvement of special areas is associated with worse quality of life and depression. 35-71% of patients with 10% or less total BSA involvement experienced a moderate-to-extremely large effect on these life function domains. When adjusting for age, sex, and body surface area, psoriasis involvement of a special location was associated with poorer patient reported outcomes. including a 46% less likelihood of reporting their skin disease ass having “no or only a small effect on QoL,” a 30% less likelihood of having a “normal l ability to participate in social roles and activities,” and a 126% higher likelihood of f having depression. Conclusion: Real-world data presented here demonstrate that psoriasis involving special areas is associated with adverse life consequences, including poor quality of life and depression.
PSORIASIS SEVERITY: COMMONLY USED CLINICAL THRESHOLDS MAY NOT ADEQUATELY CONVEY PATIENT IMPACT
|Golbari NM, van der Walt JM, Blauvelt A, Ryan C, van de Kerkhof P, Kimball AB. J Eur Acad Dermatol Venereol. 2020 Sep 25. doi: 10.1111/jdv.16966.
Psoriasis severity is usually evaluated using quantitative and qualitative measures, including percent body surface area (BSA) involvement, the Psoriasis Area and Severity Index (PASI), and the Dermatology Life Quality Index (DLQI), a patient -reported questionnaire. However, standardized definitions for psoriasis severity categories have not been well established. A PASI of 10 or 12 has remained the minimal severity threshold defining eligibility for psoriasis treatments. In the present study, the validity of this cut-off was re-evaluated in the context of quality of life.
To determine if the thresholds commonly used to define moderate psoriasis (PASI of 10-12 and BSA of 10) are supported by patient-reported DLQ I data.
A systematic review of randomized controlled trials that enrolled mild or moderate patients published between January 2000 – June 2017 was used to assess correlations between provider and patient-generated severity at baseline.
For subject groups with high impact on quality of life (DLQI >10), the mean weighted BSA was 7.6 (Range: 7.1 -8.4) and the mean weighted DLQI was 11 (Range: 10.2 – 12.2). Similarly, the mean weighted PASI for patients with DLQI >10 was 8.7 (Range: 7.1 – 10.1) and the mean weighted DLQI was 10.9 (Range: 10.1 -12.2). Conclusion: Patients with PASI or BSA scores less than 10 can have major quality of life impairment. In general, the objective measures of BSA and PASI alone, when excluding DLQI, may not fully capture the impact of disease severity.
RECATEGORIZATION OF PSORIASIS SEVERITY: DELPHI CONSENSUS FROM THE INTERNATIONAL PSORIASIS COUNCIL
|Strober B, Ryan C, van de Kerkhof P, van der Walt J, Kimball AB, Barker J, Blauvelt A. Journal of the American Academy of Dermatology (2019), doi: https://doi.org/10.1016/ j.jaad.2019.08.026.
Psoriasis severity categories have been important tools for clinicians to use in treatment decisions as well as to determine eligibility criteria for clinical studies. However, owing to the heterogeneity of severity classifications and their lack of consideration for the impact of psoriasis involvement of special areas or past treatment history, patients may be miscategorized, which can lead to undertreatment of psoriasis.
View more resources on utilizing this new categorization in your clinic.
Support Our Work